Rebalix
Logo InvescoInvesco · sheet of 10 September 2026
ETF sheet · official issuer and register data

Invesco JPX-Nikkei 400 UCITS ETF USD Hdg Acc

N4US · IE00BVGC6751 · class USD Hdg Acc · USD · domicile Ireland
Equity · JapanUSD-hedged share classSFDR art. 6
Index tracked: JPX-Nikkei 400 Net Total Return USD Hedged Index
TER
0.19%+ trans. 0.20%
Fund size
1 m EUR
Tracking difference
−0.50%3-year avg
🇮🇹 tax rate
26.00%white list 0.00%
Replication
Synthetic (swap)
Income
Accumulating
Launch 10 Mar 2015 · costs from the KID as of 14 Aug 2026 · 61 securities held · 2 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 2 Sept 2026
Investment objective: The objective of the Fund is to achieve the performance of the JPX-Nikkei 400 Net Total Return Index (the "Index"), less fees, expenses and transaction costs. Dividend Policy: This Share Class does not pay you income, but instead reinvests it to grow your capital, in line with its stated objectives. Redemption and Dealing of Shares: The Fund's shares are listed on one or more Stock Exchange(s). Investors can buy or sell shares daily through an intermediary directly or on Stock Exchange(s) on which the shares are traded. In…

Performance since series start (in euro) — base 100

10 Mar 201513 Aug 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
20162018202020222024202639077390
High 390 (13 Aug 2026) · low 77 (8 Jul 2016) · last 390. Past performance is not indicative of future results.

Returns in euro

1 year+44.4%
3 years+106.9%
5 years+186.7%
10 years+364.8%
Since series start+290.1%

Risk · 1 / 3 / 5 years

Volatility (ann.)20.97%22.48%20.19%
Max drawdown−11.03%−25.28%−25.28%
Sharpe1.511.080.95
Sortino2.261.531.35
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · N4US · IE00BVGC67511
RebalixN4US · IE00BVGC6751 · sheet of 10 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · from issuer-declared series
YearFundIndexTD
2025+28.36%+28.84%−0.49%
2024+25.69%+26.18%−0.49%
2023+34.89%+35.41%−0.52%
2022−0.74%−0.35%−0.39%
2021+11.82%+12.25%−0.43%

Holdings

Synthetic replication: top positions of the substitute basket (swap collateral), not the fund’s exposure · 31 Aug 2026 · 61 securities · top-10 weight = 39.8%
Top holdingsWeight
AMAZON.COM INC6.4%
ALNYLAM PHARMACEUTICALS INC5.3%
NVIDIA CORP3.9%
FISERV INC3.9%
BROADCOM INC3.5%
CORPAY INC3.4%
ADOBE INC3.4%
HALOZYME THERAPEUTICS INC3.3%
MICRON TECHNOLOGY INC3.3%
GENERAC HOLDINGS INC3.3%

Listing venues

ESMA register (FIRDS) and official exchange lists
SC09 · Börse Düsseldorf, Börse München / gettex
+ 6 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.invesco.com/content/dam/invesco/emea/en/product-documents/etf/shar
Factsheet · www.invesco.com/content/dam/invesco/emea/en/product-documents/etf/shar
Prospectus · www.invesco.com/content/dam/invesco/emea/en/product-documents/etf/umbr
The live sheet, always up to date
rebalix.com/en/etf/IE00BVGC6751
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · N4US · IE00BVGC67512